InMode (INMD)
(Delayed Data from NSDQ)
$19.06 USD
+1.23 (6.90%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $19.00 -0.06 (-0.31%) 7:58 PM ET
5-Strong Sell of 5 5
B Value D Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
INMD 19.06 +1.23(6.90%)
Will INMD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for INMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INMD
InMode (INMD) Q1 Earnings and Revenues Beat Estimates
TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates
INMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Stryker (SYK) Beats Q1 Earnings and Revenue Estimates
Earnings Preview: InMode (INMD) Q1 Earnings Expected to Decline
InMode (INMD) Ascends But Remains Behind Market: Some Facts to Note
Other News for INMD
InMode to Report Second Quarter 2024 Financial Results and Hold Conference Call on Aug. 1, 2024
InMode: Reversing Previous Shareholder Dilution With Buybacks
The most crowded longs and shorts in U.S. Med-Tech for May - UBS
InMode to Present at Jefferies Healthcare Conference
InMode: Facing A Myraid Of Headwinds